American Premium Water Corp (OTC: HIPH) Could Potentially Surge More Than 600% Based on Recent Price Targets and Financing Agreements


NEW YORK, Feb. 11, 2019 (GLOBE NEWSWIRE) -- SmallCapTips Commentary –

American Premium Water Corporation (OTC:HIPH) rallied last year over 1000%, and is now sitting below its prior resistance levels. The stock has been trending upward lately, and if HIPH were to break through its January highs, it will signal potentially another wave were it will reach higher values, so short-term traders could look for a break above the key resistance levels for an entry point. Normally this kind of bounce back is seen as a short-term turning point.

The stock price, which closed last week at $0.0609, is trading above its 50 and 200-day moving averages, which has historically indicated a bullish trend for the medium and long-term.  HIPH has been making higher top and higher bottoms within the past 20 trading days with the daily volume rising over the same period, which is indicated on its daily chart.

Evaluating the qualitative factors of the Company’s business, HIPH recently announced an acquisition of a CBD cosmetics brand plant + body and a CBD vape brand Evoxe Laboratories. The Company has been focusing on acquisitions in the CBD space to compliment their CBD infused water business. HIPH has proprietary ‘hydro-nano’ formulations that utilize nano-technology that increases the CBD’s bioavailability, which increases the rate of absorption into the bloodstream. SmallCap Tips is bullish on their focus on CBD technology and believes the technical indicators are coming in line with the moves that the Company has been making.   

Recent Research Highlights

  • SeeThru Equity, the leading small and microcap research firm, recently upgraded its price target for HIPH from $0.15 to $0.30
  • Ludlow Research recently provided a short, speculative price target for the Company of $0.15-$0.20 a share
  • The Company recently entered into a financing agreement that gave it a $0.40 valuation
  • Zacks Investment Research has a neutral view of the Company
  • Barchart currently gives the Company a “Buy” rating

For commentary inquiries, please contact: info@smallcaptips.com

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected”, “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SmallCapTips undertakes no obligation to update such statements. SmallCapTips was not compensated by (OTC:HIPH) or any other company mentioned in this article, You should not rely on the information presented; you should do independent research to form your own opinion and decision. Information contained in our disseminated emails does not constitute investment, legal or tax advice upon which you should rely. The purchase of high-risk securities may result in the loss of your entire investment. Advertisements received by you are not a solicitation or recommendation to buy securities of the advertised company.